Remission of severe myasthenia gravis after autologous stem cell transplantation
Monica I. Schlatter(Colorado Blood Cancer Institute), George E. Georges(Northwestern University), Marie Provost(Colorado Blood Cancer Institute), Michael Pearlman(Sarah Cannon), James D. Bowen(Swedish Medical Center), Michael Tees(Sarah Cannon), Richard A. Nash(Colorado Blood Cancer Institute), Abeer Obaid(Yale University), Richard J. Nowak(Yale University), Minh Pham(Yale University), Callee Redman(Colorado Blood Cancer Institute), Soumya S. Yandamuri(University of Utah), Peter A. McSweeney(Mesoblast (United States)), Kevin C. O’Connor(Yale University)
Cited by 12
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k